Brett R. Hagen

Brett R. Hagen (senior executive) discloses dealings in Kalaris Therapeutics, Inc. to SEC (Form 4). Between 18 January 2022 and 20 March 2026, the trades on record add up to 42 filings.

Sales make up the whole of the open-market record (38 sales, €167k). Other entries cover 4 share grants. 2026 to date brings no purchases and 1 sale.

Most recently, on 23 March 2026, the filings show an open-market sale worth €11k in Kalaris Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.